Show simple item record

dc.contributor.authorShiek Ahmad, B.
dc.contributor.authorPetty, S.
dc.contributor.authorGorelik, A.
dc.contributor.authorO Brien, T.
dc.contributor.authorHill, Keith
dc.contributor.authorChristie, J.
dc.contributor.authorSambrook, P.
dc.contributor.authorWark, J.
dc.date.accessioned2017-07-27T05:22:26Z
dc.date.available2017-07-27T05:22:26Z
dc.date.created2017-07-26T11:11:14Z
dc.date.issued2017
dc.identifier.citationShiek Ahmad, B. and Petty, S. and Gorelik, A. and O Brien, T. and Hill, K. and Christie, J. and Sambrook, P. et al. 2017. Bone loss with antiepileptic drug therapy: a twin and sibling study. Osteoporosis International: pp. 1-10.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/54859
dc.identifier.doi10.1007/s00198-017-4098-9
dc.description.abstract

© 2017 International Osteoporosis Foundation and National Osteoporosis FoundationSummary: Changes in areal bone mineral density (aBMD) and other predictors of bone loss were evaluated in 48 same-sex twin/age-matched sibling pairs discordant for antiepileptic drug (AED) use. AED users had reduced BMD at the hip regions. Prolonged AED users had greater aBMD loss, predicting a higher risk of bone fragility. Introduction: To investigate the longitudinal associations of bone mineral measures with antiepileptic drug (AED) use, including enzyme-inducing (EIAED) and non-enzyme-inducing (NEIAED) types, and other predictors of bone loss in a study of 48 same-sex twin/age-matched sibling pairs (40 female, 8 male) discordant for AED use. Methods: Using dual-energy X-ray absorptiometry (DXA), areal bone mineral density (aBMD) and content (BMC) at the hip regions, forearm, lumbar spine, and whole body were measured twice, at least 2 years apart. The mean within-pair difference (MWPD), MWPD%, and mean annual rate of aBMD change were adjusted for age, weight, and height. Predictors of bone loss were evaluated. Results: AED users, compared to non-users, at baseline and follow-up, respectively, had reduced aBMD at the total hip (MWPD% 3.8, 4.4%), femoral neck (4.7, 4.5%), and trochanter regions (4.1, 4.6%) (p < 0.05). For the whole cohort, the annual rate of change in all aBMD/BMC (p > 0.05) regions did not differ within pairs. Nevertheless, EIAED users had greater aBMD loss than non-users (n = 20 pairs) at the total hip (1.7 vs. 0.3%, p = 0.013) and whole body regions (0.7% loss vs. 0.1% BMD gain, p = 0.019), which was not found in NEIAED-discordant pairs (n = 16). AED use >20 years predicted higher aBMD loss at the forearm (p = 0.028), whole body (p = 0.010), and whole body BMC (p = 0.031). Conclusions: AED users had reduced aBMD at the hip regions. Prolonged users and EIAED users had greater aBMD loss, predicting a higher risk of bone fragility. Further prospective studies of AED effects on bone microarchitecture are needed.

dc.publisherSpringer
dc.titleBone loss with antiepileptic drug therapy: a twin and sibling study
dc.typeJournal Article
dcterms.source.startPage1
dcterms.source.endPage10
dcterms.source.issn0937-941X
dcterms.source.titleOsteoporosis International
curtin.departmentSchool of Physiotherapy and Exercise Science
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record